Citi: Cuts GIANT BIOGENE (02367) target price to HK$29.3, maintains "Buy" rating.

date
13:52 18/11/2026
avatar
GMT Eight
Citi said that GIANT BIOGENE's online sales performance during the Double 11 promotion was weaker than expected, and decided to initiate a 30-day negative catalyst watch.
Citi issued a research report stating that GIANT BIOGENE (02367) posted weaker-than-expected online sales during the Double 11 promotion. The bank cut its earnings forecasts by about 11% to 17%, lowered its target price from HK$38.4 to HK$29.3, maintained its "Buy" rating, but opened a 30-day negative catalyst watch. In the China cosmetics sector, the bank prefers MAO GEPING (01318). The bank believes management's target of 10% full-year revenue growth for 2026 will be difficult to achieve, and expects margin pressure to intensify amid potential operating deleverage. The bank now expects 2026 revenue growth of 2.4%, including 13.6% growth in the second half versus a 6.3% decline in the first half; net margin is expected to fall 3.7 percentage points to 31.0%, then further to 28.9% and 28.2% in 2027 and 2028, respectively. Based on revenue forecast cuts of 7.5% to 14.1% and lower operating margin assumptions, the bank lowered its net profit forecasts for 2026 to 2028 by 10.9% to 17.4%. It now expects 2026 net profit to decline 8.7%, followed by growth of 2.9% and 7.5% in 2027 and 2028, respectively.